Cargando…

Recurrent Acute Disseminated Encephalomyelitis (ADEM) after COVID-19-vaccination and after subsequent COVID-19-infection: A case report (part II)

Acute disseminated encephalomyelitis (ADEM) is an autoimmune disorder of the central nervous system (CNS), which is commonly associated to previous viral infection or immunization. Cases of ADEM with a potential relationship to both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infect...

Descripción completa

Detalles Bibliográficos
Autores principales: Poli, Khouloud, Kowarik, Markus, Hamprecht, Klaus, Iftner, Thomas, Ernemann, Ulrike, Ziemann, Ulf, Poli, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036343/
https://www.ncbi.nlm.nih.gov/pubmed/36970530
http://dx.doi.org/10.3389/fneur.2023.1149612
_version_ 1784911630958592000
author Poli, Khouloud
Kowarik, Markus
Hamprecht, Klaus
Iftner, Thomas
Ernemann, Ulrike
Ziemann, Ulf
Poli, Sven
author_facet Poli, Khouloud
Kowarik, Markus
Hamprecht, Klaus
Iftner, Thomas
Ernemann, Ulrike
Ziemann, Ulf
Poli, Sven
author_sort Poli, Khouloud
collection PubMed
description Acute disseminated encephalomyelitis (ADEM) is an autoimmune disorder of the central nervous system (CNS), which is commonly associated to previous viral infection or immunization. Cases of ADEM with a potential relationship to both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination have been reported. We recently published a rare case of a 65-year-old patient who suffered from a corticosteroid- and immunoglobulin-refractory multiple autoimmune syndrome including ADEM following Pfizer-BioNTech coronavirus disease (COVID)-19 vaccination, and whose symptoms largely resolved after repeated plasma exchange (PE). Four months later, the patient was diagnosed with SARS-CoV-2 omicron variant infection after experiencing mild upper respiratory tract symptoms. Few days later, the patient developed severe tetraparesis with magnetic resonance imaging (MRI) showing multiple new inflammatory contrast-enhancing lesions in the left middle cerebellar peduncle, cervical spinal cord, and ventral conus medullaris. Repeated cerebrospinal fluid (CSF) analyses indicated blood-brain barrier damage (increased albumin ratio) without signs of SARS-CoV-2 invasion (mild pleocytosis, no intrathecal antibody production). SARS-CoV-2 specific immunoglobulin G (IgG) were detected in serum and to a much lower degree in CSF with close correlation between both concentrations over time, reflecting antibody dynamics of vaccine- and infection-induced immune response, and blood-brain barrier patency. Daily PE therapy was initiated. Given the patient's lack of improvement after seven PE, treatment with rituximab was considered. After a first dose, however, the patient suffered epididymo-orchitis leading to sepsis, and declined rituximab continuation. At 3-months follow-up, clinical symptoms had dramatically improved. The patient regained walking ability without assistance. This case of recurrent ADEM after COVID-19-vaccination and after subsequent COVID-19-infection strongly supports the hypotheses of neuroimmunological complications in these conditions being promoted by a systemic immune response and mediated by molecular mimicry of, both, viral and vaccine SARS-CoV-2 antigens and CNS self-antigens.
format Online
Article
Text
id pubmed-10036343
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100363432023-03-25 Recurrent Acute Disseminated Encephalomyelitis (ADEM) after COVID-19-vaccination and after subsequent COVID-19-infection: A case report (part II) Poli, Khouloud Kowarik, Markus Hamprecht, Klaus Iftner, Thomas Ernemann, Ulrike Ziemann, Ulf Poli, Sven Front Neurol Neurology Acute disseminated encephalomyelitis (ADEM) is an autoimmune disorder of the central nervous system (CNS), which is commonly associated to previous viral infection or immunization. Cases of ADEM with a potential relationship to both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination have been reported. We recently published a rare case of a 65-year-old patient who suffered from a corticosteroid- and immunoglobulin-refractory multiple autoimmune syndrome including ADEM following Pfizer-BioNTech coronavirus disease (COVID)-19 vaccination, and whose symptoms largely resolved after repeated plasma exchange (PE). Four months later, the patient was diagnosed with SARS-CoV-2 omicron variant infection after experiencing mild upper respiratory tract symptoms. Few days later, the patient developed severe tetraparesis with magnetic resonance imaging (MRI) showing multiple new inflammatory contrast-enhancing lesions in the left middle cerebellar peduncle, cervical spinal cord, and ventral conus medullaris. Repeated cerebrospinal fluid (CSF) analyses indicated blood-brain barrier damage (increased albumin ratio) without signs of SARS-CoV-2 invasion (mild pleocytosis, no intrathecal antibody production). SARS-CoV-2 specific immunoglobulin G (IgG) were detected in serum and to a much lower degree in CSF with close correlation between both concentrations over time, reflecting antibody dynamics of vaccine- and infection-induced immune response, and blood-brain barrier patency. Daily PE therapy was initiated. Given the patient's lack of improvement after seven PE, treatment with rituximab was considered. After a first dose, however, the patient suffered epididymo-orchitis leading to sepsis, and declined rituximab continuation. At 3-months follow-up, clinical symptoms had dramatically improved. The patient regained walking ability without assistance. This case of recurrent ADEM after COVID-19-vaccination and after subsequent COVID-19-infection strongly supports the hypotheses of neuroimmunological complications in these conditions being promoted by a systemic immune response and mediated by molecular mimicry of, both, viral and vaccine SARS-CoV-2 antigens and CNS self-antigens. Frontiers Media S.A. 2023-03-10 /pmc/articles/PMC10036343/ /pubmed/36970530 http://dx.doi.org/10.3389/fneur.2023.1149612 Text en Copyright © 2023 Poli, Kowarik, Hamprecht, Iftner, Ernemann, Ziemann and Poli. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Poli, Khouloud
Kowarik, Markus
Hamprecht, Klaus
Iftner, Thomas
Ernemann, Ulrike
Ziemann, Ulf
Poli, Sven
Recurrent Acute Disseminated Encephalomyelitis (ADEM) after COVID-19-vaccination and after subsequent COVID-19-infection: A case report (part II)
title Recurrent Acute Disseminated Encephalomyelitis (ADEM) after COVID-19-vaccination and after subsequent COVID-19-infection: A case report (part II)
title_full Recurrent Acute Disseminated Encephalomyelitis (ADEM) after COVID-19-vaccination and after subsequent COVID-19-infection: A case report (part II)
title_fullStr Recurrent Acute Disseminated Encephalomyelitis (ADEM) after COVID-19-vaccination and after subsequent COVID-19-infection: A case report (part II)
title_full_unstemmed Recurrent Acute Disseminated Encephalomyelitis (ADEM) after COVID-19-vaccination and after subsequent COVID-19-infection: A case report (part II)
title_short Recurrent Acute Disseminated Encephalomyelitis (ADEM) after COVID-19-vaccination and after subsequent COVID-19-infection: A case report (part II)
title_sort recurrent acute disseminated encephalomyelitis (adem) after covid-19-vaccination and after subsequent covid-19-infection: a case report (part ii)
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036343/
https://www.ncbi.nlm.nih.gov/pubmed/36970530
http://dx.doi.org/10.3389/fneur.2023.1149612
work_keys_str_mv AT polikhouloud recurrentacutedisseminatedencephalomyelitisademaftercovid19vaccinationandaftersubsequentcovid19infectionacasereportpartii
AT kowarikmarkus recurrentacutedisseminatedencephalomyelitisademaftercovid19vaccinationandaftersubsequentcovid19infectionacasereportpartii
AT hamprechtklaus recurrentacutedisseminatedencephalomyelitisademaftercovid19vaccinationandaftersubsequentcovid19infectionacasereportpartii
AT iftnerthomas recurrentacutedisseminatedencephalomyelitisademaftercovid19vaccinationandaftersubsequentcovid19infectionacasereportpartii
AT ernemannulrike recurrentacutedisseminatedencephalomyelitisademaftercovid19vaccinationandaftersubsequentcovid19infectionacasereportpartii
AT ziemannulf recurrentacutedisseminatedencephalomyelitisademaftercovid19vaccinationandaftersubsequentcovid19infectionacasereportpartii
AT polisven recurrentacutedisseminatedencephalomyelitisademaftercovid19vaccinationandaftersubsequentcovid19infectionacasereportpartii